Form 4: IGMS Director Reports Share Conversion Post-Merger

IGM Biosciences, Inc. director William Strohl reported the conversion of his common stock holdings into cash and contingent value rights following the company's merger with Concentra Biosciences.

Summary

• IGM Biosciences, Inc. completed a merger on August 14, 2025, with Merger Sub, a wholly owned subsidiary of Concentra Biosciences, LLC, resulting in IGM Biosciences becoming a wholly owned subsidiary of Concentra Biosciences.
• Each issued and outstanding share of IGM Biosciences' Common Stock was cancelled and converted into the right to receive $1.247 in cash and one contractual Contingent Value Right (CVR).
• Director William Strohl reported the disposition of 125,000 shares of Common Stock, resulting in zero beneficially owned shares following the transaction, consistent with the merger terms.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shareholders lose direct equity, they receive immediate cash and potential future value via CVRs from a pre-announced merger, which is an expected outcome. The CVR introduces some uncertainty, preventing a higher score.

Positives

• Shareholders received a cash payment of $1.247 per share, providing immediate liquidity.
• Shareholders also received a Contingent Value Right (CVR), offering potential future value based on specific terms and conditions.
• The merger provides a definitive exit strategy for existing public shareholders of IGM Biosciences.

Negatives

• IGM Biosciences, Inc. common stock was cancelled, meaning shareholders no longer hold direct equity in the company.
• The company is now a wholly owned subsidiary, indicating a loss of independent public trading status.
• The value of the Contingent Value Right (CVR) is contingent and not guaranteed, introducing uncertainty for future returns.

Risks

• The value of the Contingent Value Right (CVR) is uncertain and depends on future events or milestones, which may not be achieved.
• Former shareholders no longer participate in the future growth or potential upside of IGM Biosciences beyond the specific terms of the CVR.

Future Outlook

The filing indicates the completion of a merger, resulting in IGM Biosciences, Inc. becoming a wholly owned subsidiary of Concentra Biosciences, LLC. The future outlook for former IGM Biosciences shareholders is tied to the performance and terms of the Contingent Value Rights (CVRs) received.

Industry Context

This transaction represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies are often acquired by larger entities for their pipeline, technology, or market position. Such mergers can provide an exit for investors and integrate promising assets into a broader portfolio.

Comparison to Industry Standards

• The structure of the deal, involving a cash component and a Contingent Value Right (CVR), is a common mechanism in biotech mergers, particularly when the acquired company has pipeline assets with uncertain future milestones. This allows the acquirer to limit upfront costs while providing potential upside to the acquired company's shareholders if specific clinical or regulatory achievements are met.
• Comparable deals often include CVRs tied to clinical trial success, regulatory approvals (e.g., FDA approval), or commercialization milestones. For instance, the acquisition of Acceleron Pharma by Merck included CVRs tied to specific regulatory approvals for sotatercept.
• The cash component of $1.247 per share provides immediate, certain value, which is typical in such transactions to ensure a baseline return for shareholders.

Stakeholder Impact

• Shareholders: Received cash and CVRs in exchange for their shares, ending their direct equity ownership in the publicly traded entity.
• Employees: The filing does not provide specific details on employee impact, but mergers often lead to organizational restructuring.
• Creditors: The filing does not provide specific details on creditor impact.

Next Steps

• Former IGM Biosciences shareholders will monitor the progress of the Contingent Value Rights (CVRs) for potential future payouts based on their terms and conditions.

Key Dates

Keywords

IGM Biosciences, IGMS, Concentra Biosciences, Merger, Acquisition, Form 4, SEC Filing, Contingent Value Right, CVR, Stock Conversion, Director Transaction